In the global scientific and commercial race for the first shot of the COVID-19 vaccine, the play of geopolitics is very much in evidence as U.
S.-based Pfizer and Russia’s Gamaleya claim that phase 3 trials enjoy shown 90 per cent efficacy of their vaccine candidates.
Source: frontline.in